Biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030 by roots

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html

 

Key Market Insights

• Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products.
• The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies.
• Case study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years.
• The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters.
• The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters.
• With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for the development and manufacturing of cell therapies and antibodies.
• In order to cater the increasing demand for biologics, stake holders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported.
• We expect the developers to continue to outsource their manufacturing operations in the short to mid-term, resulting in an annualized growth rate of more than 8%.
• In the long term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers

 

For more information, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Table of Contents

 

1.          PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.          EXECUTIVE SUMMARY

 

3.          INTRODUCTION

3.1.       Context and Background

3.2.       An Overview of Biopharmaceuticals

3.3.       Biopharmaceutical Manufacturing

3.3.1.    Types of Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Fungal Expression Systems

3.3.1.4. Insect Expression Systems

3.3.1.5. Plant Expression Systems

3.3.1.6. Mammalian Expression Systems

 

3.3.2.    Manufacturing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

 

3.4.       An Overview of Contract Manufacturing

3.5.       Need for Outsourcing in the Biopharmaceutical Industry

3.6.       Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7.       Basic Guidelines for Selecting a CMO Partner

3.8.       Advantages of Outsourcing Manufacturing Services

3.9.       Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.10.     Concluding Remarks

 

4.         COMPETITIVE LANDSCAPE

4.1.       Chapter Overview

4.2.       Biopharmaceuticals Contract Manufacturers: Overall Market Landscape

4.2.1.    Analysis by Size of Employee Base

4.2.2.    Analysis by Location of Headquarters

4.2.3.    Analysis by Year of Establishment

4.2.4.    Analysis by Location of Manufacturing Facilities

4.2.5.    Analysis by Type of Biologics Manufactured

4.2.6.    Analysis by Scale of Operation

4.2.7.    Analysis by Expression Systems

4.2.8.    Analysis by Type of Bioreactor and Modes of Operation

4.2.9.    Analysis by Biomanufacturing Capacity

4.2.10.  Analysis by Packaging Form

4.3.       Concluding Remarks

 

5.         BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

5.1.       Chapter Overview

5.2.       Biopharmaceutical Outsourcing in the US: Regulatory Scenario

5.2.1.    Impact of Current Political Situation

5.3.       Leading Biopharma CMOs in North America

5.3.1.    AMRI (OsoBio)

5.3.1.1. Company Overview

5.3.1.2. Services Portfolio

5.3.1.3. Financial Information

5.3.1.4. Manufacturing Facilities

5.3.1.5. Partnerships

5.3.1.6. Recent Developments

5.3.1.7. Future Outlook

 

5.3.2.    Baxter BioPharma Solutions

5.3.2.1. Company Overview

5.3.2.2. Services Portfolio

5.3.2.3. Financial Information

5.3.2.4. Manufacturing Facilities

5.3.2.5. Partnerships

5.3.2.6. Recent Developments

5.3.2.7. Future Outlook

 

5.3.3.    Catalent Biologics (Catalent Pharma Solutions)

5.3.3.1. Company Overview

5.3.3.2. Services Portfolio

5.3.3.3. Financial Information

5.3.3.4. Manufacturing Facilities

5.3.3.5. Partnerships

5.3.3.6. Recent Developments

5.3.3.7. Future Outlook

 

5.3.4.    Cytovance Biologics

5.3.4.1. Company Overview

5.3.4.2. Services Portfolio

5.3.4.3. Partnerships

5.3.4.4. Recent Developments

5.3.4.5. Future Outlook

 

5.3.5.    Patheon

5.3.5.1. Company Overview

5.3.5.2. Services Portfolio

5.3.5.3. Financial Information

5.3.5.4. Manufacturing Facilities

5.3.5.5. Partnerships

5.3.5.6. Recent Developments

5.3.5.7. Future Outlook

 

5.3.6.    Piramal Pharma Solutions

5.3.6.1. Company Overview

5.3.6.2. Services Portfolio

5.3.6.3. Financial Information

5.3.6.4. Facilities

5.3.6.5. Partnerships

5.3.6.6. Recent Developments

5.3.6.7. Future Outlook

 

6.         BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

6.1.       Chapter Overview

6.2.       Biopharmaceutical Outsourcing in Europe: Regulatory Scenario

6.3.       Leading Biopharmaceutical CMOs in Europe

6.3.1.    3P Biopharmaceuticals

6.3.1.1. Company Overview

6.3.1.2. Services Portfolio

6.3.1.3. Manufacturing Facilities

6.3.1.4. Partnerships

6.3.1.5. Recent Developments

6.3.1.6. Future Outlook

 

6.3.2.    Boehringer Ingelheim BioXcellence™

6.3.2.1. Company Overview

6.3.2.2. Services Portfolio

6.3.2.3. Financial Information

6.3.2.4. Manufacturing Facilities

6.3.2.5. Partnerships

6.3.2.6. Recent Developments

6.3.2.7. Future Outlook

 

6.3.3.    Celonic

6.3.3.1. Company Overview

6.3.3.2. Services Portfolio

6.3.3.3. Manufacturing Facilities

6.3.3.4. Partnerships

6.3.3.5. Recent Developments

6.3.3.6. Future Outlook

 

6.3.4.    FUJIFILM Diosynth Biotechnologies

6.3.4.1. Company Overview

6.3.4.2. Services Portfolio

6.3.4.3. Financial Information

6.3.4.4. Manufacturing Capabilities

6.3.4.5. Partnerships

6.3.4.6. Recent Developments

6.3.4.7. Future Outlook

 

6.3.5.    LFB Group

6.3.5.1. Company Overview

6.3.5.2. Services Portfolio

6.3.5.3. Financial Information

6.3.5.4. Manufacturing Facilities

6.3.5.5. Partnerships

6.3.5.6. Recent Developments

6.3.5.7. Future Outlook

 

6.3.6.    Lonza

6.3.6.1. Company Overview